Gland Pharma Ltd

The transcript provided does not explicitly mention any current or future fundraising plans through debt or equity for Gland Pharma Limited. Key points related to financials and investments are: - Gland Pharma plans capital expenditure (CAPEX) of around €60 million over three years for capacity and capability expansion, particularly related to Cenexi. - The company has sufficient visibility of pipeline and business interest, indicating internal funding or cash flow is likely being used. - There is no direct reference to raising funds via debt or equity in the provided pages. - Discussions primarily focus on operational performance, capacity expansion, margin improvements, and growth guidance rather than capital raising activities. Therefore, no clear information on new fundraising activities through debt or equity exists in the document excerpts provided.

- Investment of about INR 120 crores planned for a new cartridge line, expected to be installed by the end of this year. - A ~60 million euro CAPEX over the next 2-3 years in Cenexi to increase capability and capacity, including: - Adding a new pre-filled syringe line at Hérouville site for better realization per unit. - Adding an additional vial line and lyophilization capacity in the Belgium site to boost high-value business. - Focus on replacing inefficient lines and adding new capacities for lyophilized (Lyo) products to meet growing demand. - Capacity expansion driven by supply constraints at two sites unable to cater to demand, particularly for Lyo products. - Strategic investments aim for Cenexi to reach ~300 million euro revenue in 3 years with high teens EBITDA margin. - Long-term investment designed to improve efficiencies, support pipeline growth, and enable cross-selling synergies.

- FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin. - Consolidated growth guidance for next year (FY'26): mid-teen percentage growth (~15%). - Key US growth drivers FY'26: improvement in Cenexi numbers, new product launches, tech transfer projects, dry powder contracts (~Rs 60-70 crores), biologics (~Rs 100 crores). - US volume growth notable in top products (24% volume increase in top 10 products). - GLP cartridge fill-and-finish market expected to expand significantly; capacity to increase to 140 million cartridges next year from 40 million. - ROW business expected to double over next 3-5 years via product registrations and cost efficiencies. - Cenexi to break even by December quarter, aiming for double-digit EBITDA margin in FY'27. - Milestone and profit share income expected to increase with more product launches. - Mid-teens growth next year for consolidated business; low-20s growth in subsequent 2 years.

- Cenexi's current order book is around Euro 100 million (Page 22). - Cenexi has capacity constraints at two sites due to inefficient lines, leading to aggressive capacity expansion (Pages 20-21). - The company is investing in new and more efficient lines to meet demand, particularly for lyophilized products (Page 21). - For GLP (glucagon-like peptide) fill and finish, 40 million cartridges capacity is mostly booked; the second line will be operational by year-end to cater to additional partnerships (Pages 22-23). - The company anticipates strong volume increases for GLP products with market demand expected to grow significantly (Pages 14-15). - Pending regulatory approvals and product pipeline remain significant, with approximately 500 registrations pending to support growth (Page 12).

- FY'26 overall growth guidance: mid-teens percentage (15%-17%), driven by US business growth, new launches, tech transfer projects, dry powder contracts, and biologics segment (~Rs 100 crores revenue expected in FY'26). - Subsequent 2 years growth forecast: low-20% range. - EBITDA margin: double-digit EBITDA margin expected in FY'27, with margin expansion driven by operating leverage and added capacity without proportional increase in manpower costs. - Cenexi business margins expected to improve and reach double-digit EBITDA next year. - Milestone and profit share income expected to contribute positively on a yearly basis though not consistent quarterly. - Rest of business margins stable around 37%-38% and expected to maintain/improve. - GLP (Generic Large Volume Parenteral) segment positioning to grow significantly, potentially accelerating growth trajectory. Overall, company anticipates strong earnings growth fueled by volume expansion, new product launches, operational efficiencies, and capacity additions.